Use of monoclonal antibodies in human transplantation.
Monoclonal antibodies are of growing importance in human organ transplantation in the prophylatic and curative treatment of cellular rejection. Among the pan T-lymphocyte monoclonal antibodies, OKT3 has been much studied, although clinical research is engaged with more selective targets of allorecognition and/or their consequences, for example monoclonal antibodies directed against the interleukin-2 receptor, adhesion molecules and CD4 molecules. We summarize the use of these monoclonal antibodies and bioreagents in clinical transplantation.
Dantal
J
J
Clinic of Immunology and Research Unit INSERM, Nantes, France.
Soulillou
J P
JP
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000276:immunology; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000276:immunology; D006801:Humans; D051379:Mice; D016853:Muromonab-CD3 / Q000276:immunology; D011446:Prospective Studies; D051381:Rats; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology; D014181:Transplantation Immunology
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D011993:Recombinant Fusion Proteins